The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

Novavax Inc. closed 59.74% below its 52-week high of $17.81, which the company achieved on July 26th.

Conversations with the Trump administration on its “most favored nation” policy have been productive, the executive said ...

Novavax Inc. closed 60.92% short of its 52-week high of $17.81, which the company reached on July 26th.

Vinay Prasad overruled other reviewers for a third time in recent months in clearing only narrow use of Moderna's vaccine in young children.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.